An inhibitor of squalene epoxidase, NB-598, suppresses the secretion of cholesterol and triacylglycerol and simultaneously reduces apolipoprotein B in HepG2 cells.
NB-598, a specific inhibitor of squalene epoxidase, suppressed the secretion of cholesterol and triacylglycerol from HepG2 cells into the medium. L-654,969, an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, inhibited the secretion of cholesterol as potently as NB-598, but did not suppress the secretion of triacylglycerol. Both compounds decreased the intracellular cholesterol content almost equally, and neither of the compounds reduced the intracellular triacylglycerol content. The suppression of lipid secretion by NB-598 was associated with a significant reduction in apolipoprotein (apo) B secretion into the medium. Therefore, the suppression of lipid secretion by NB-598 may be caused by a reduction in the number of triacylglycerol-rich lipoprotein particles. In contrast, the suppression of cholesterol secretion by L-654,969 may be due to a modulation of lipoprotein lipid composition, since this agent did not reduce the secretion of apo B or triacylglycerol. The secretion of apo A-I was unaffected by either NB-598 or L-654,969. Pulse chase studies using [35S]methionine showed that the suppression of apo B secretion by NB-598 depended on an enhancement of intracellular degradation of apo B. These results indicate that the secretion of apo B from HepG2 cells is not regulated by the lipid synthesis alone, and suggest that the mechanism of the hypolipidemic effect of NB-598 involves the suppression of triacylglycerol-rich lipoprotein secretion from the liver as well as an inhibition of cholesterol synthesis in the liver.
Horie
M
M
Tsukuba Research Institute, Banyu Pharmaceutical Co., Ltd., Japan.
Hayashi
M
M
Satoh
T
T
Hotta
H
H
Nagata
Y
Y
Ishida
F
F
Kamei
T
T
D000924:Anticholesteremic Agents / Q000494:pharmacology*; D016632:Apolipoprotein A-I / Q000096:biosynthesis / Q000378:metabolism; D001055:Apolipoproteins B / Q000096:biosynthesis / Q000378:metabolism*; D001596:Benzylamines / Q000494:pharmacology*; D002784:Cholesterol / Q000378:metabolism*; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D008099:Liver / Q000187:drug effects / Q000378:metabolism; D008148:Lovastatin / Q000031:analogs & derivatives / Q000494:pharmacology; D010105:Oxygenases / Q000037:antagonists & inhibitors*; D019821:Simvastatin / Q000031:analogs & derivatives*; D013185:Squalene / Q000378:metabolism; D050603:Squalene Monooxygenase; D013876:Thiophenes / Q000494:pharmacology*; D014280:Triglycerides / Q000378:metabolism*; D014407:Tumor Cells, Cultured
D000924:Anticholesteremic Agents; D016632:Apolipoprotein A-I; D001055:Apolipoproteins B; D001596:Benzylamines; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D013876:Thiophenes; D014280:Triglycerides; C066059:NB 598; D013185:Squalene; D002784:Cholesterol; C063287:simvastatin acid; D008148:Lovastatin; D019821:Simvastatin; D010105:Oxygenases; D050603:Squalene Monooxygenase